Keiko Yanagihara1,*, Masato Yoshida2, Kensaku Awaji2, Tamami Yamakawa1, Sena Kato1, Miki Tamura1, Koji Nagata3
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891
- 30 December 2025
Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >
Login
Register
